ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 057,80
-0,92%
Dow Jones
38 852,86
-0,55%
DAX
18 677,87
-0,45%
Brent Oil
84,325
1,79%
Bitcoin
68 219,26
-1,69%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Athira Pharma Inc (ATHA)

  7. Athira Pharma Inc (ATHA) Actualités

ATHA

Athira Pharma (ATHA)

Athira Pharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ATHA
DateHeureSourceTitreSymboleSociété
25/05/202401h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATHAAthira Pharma Inc
17/05/202423h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATHAAthira Pharma Inc
17/05/202423h00GlobeNewswire Inc.Athira Pharma Announces Proposed Settlement of Stockholder Derivative ActionNASDAQ:ATHAAthira Pharma Inc
15/05/202422h05GlobeNewswire Inc.Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business UpdatesNASDAQ:ATHAAthira Pharma Inc
02/05/202413h00GlobeNewswire Inc.Athira Pharma to Participate in Upcoming May ConferencesNASDAQ:ATHAAthira Pharma Inc
15/04/202413h00GlobeNewswire Inc.Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical OfficerNASDAQ:ATHAAthira Pharma Inc
11/04/202413h00GlobeNewswire Inc.Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s DiseaseNASDAQ:ATHAAthira Pharma Inc
03/04/202413h00GlobeNewswire Inc.Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual MeetingNASDAQ:ATHAAthira Pharma Inc
08/03/202413h00GlobeNewswire Inc.Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International ConferenceNASDAQ:ATHAAthira Pharma Inc
22/02/202422h34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ATHAAthira Pharma Inc
22/02/202422h05GlobeNewswire Inc.Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business UpdatesNASDAQ:ATHAAthira Pharma Inc
16/02/202422h40Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ATHAAthira Pharma Inc
08/02/202422h02GlobeNewswire Inc.Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)NASDAQ:ATHAAthira Pharma Inc
08/01/202413h00GlobeNewswire Inc.Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business UpdateNASDAQ:ATHAAthira Pharma Inc
03/01/202413h00GlobeNewswire Inc.Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s DiseaseNASDAQ:ATHAAthira Pharma Inc
12/12/202313h00GlobeNewswire Inc.Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy BodiesNASDAQ:ATHAAthira Pharma Inc
29/11/202313h00GlobeNewswire Inc.Athira Pharma to Participate in Sidoti December Small Cap Investor ConferenceNASDAQ:ATHAAthira Pharma Inc
28/11/202313h00GlobeNewswire Inc.Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MNDNASDAQ:ATHAAthira Pharma Inc
15/11/202314h15GlobeNewswire Inc.Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s DiseaseNASDAQ:ATHAAthira Pharma Inc
09/11/202322h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATHAAthira Pharma Inc
09/11/202322h05GlobeNewswire Inc.Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business UpdatesNASDAQ:ATHAAthira Pharma Inc
08/11/202313h00GlobeNewswire Inc.Athira Pharma to Participate in Jefferies London Healthcare ConferenceNASDAQ:ATHAAthira Pharma Inc
05/10/202322h30GlobeNewswire Inc.Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)NASDAQ:ATHAAthira Pharma Inc
28/09/202313h00GlobeNewswire Inc.Athira Pharma to Participate in Upcoming October ConferencesNASDAQ:ATHAAthira Pharma Inc
19/09/202313h00GlobeNewswire Inc.Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:ATHAAthira Pharma Inc
10/08/202322h05GlobeNewswire Inc.Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business UpdatesNASDAQ:ATHAAthira Pharma Inc
17/07/202313h00GlobeNewswire Inc.Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s DiseaseNASDAQ:ATHAAthira Pharma Inc
06/07/202313h00GlobeNewswire Inc.Athira Pharma Announces Upcoming Presentations at the Alzheimer’s Association International Conference (AAIC) 2023NASDAQ:ATHAAthira Pharma Inc
09/06/202323h07Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATHAAthira Pharma Inc
31/05/202313h00GlobeNewswire Inc.Athira Pharma to Participate in Upcoming June ConferencesNASDAQ:ATHAAthira Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:ATHA

Dernières Valeurs Consultées

ASX
BLR
Black Range Minerals
EU
EDFAI
Electricite de France
NASDAQ
OSIP
Osi Pharmaceuticals
USOTC
NMEX
Northern Minerals and Ex... (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés